Coherus BioSciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Coherus BioSciences (Redwood City, CA): 4 reconciled FDA prescription therapies, $52.9M 2024 CMS Part D & Medicaid spend, and $8,892 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterRedwood City, CA
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$52.9M
2024 Medicare Part D Spend$21.2M
2024 Medicaid Spend$31.7M
California HCAI SB 17 FilingsSpecialty launch notice ($8,892 intro WAC)